Filing Flows › International Stem Cell (ISCO) › Q3 2025
International Stem Cell (ISCO) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 13, 2025
International Stem Cell (ISCO) reported revenue of $2.4M for the third quarter 2025 (Q3 2025), +9% from a year earlier and -3% from the quarter before. Operating margin was 4.0%, net earnings $57K (2.4% of revenue).
International Stem Cell, Q3 2025: revenue $2.4M (+9% year over year), operating margin 4.0%, net earnings $57K, operating cash flow $49K. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.4M | -3% | +9% |
| Operating profit | $94K | -44% | — |
| Net earnings | $57K | -56% | — |
| Operating cash flow | $49K | — | -81% |
| Free cash flow | $46K | — | -79% |
What changed
Revenue was $2.4M in Q3 2025, up 9% year over year and down 3% from the previous quarter. Biomedical Market was the largest line at 93% of revenue. Biomedical Market added $204K year over year (up 10%), 107% of the total change. Anti Aging Skincare Market declined 8%.
Operating profit was $94K, a 4.0% margin (up 8.1 points year over year). Total costs grew 0% against revenue growth of 9%. Net earnings were $57K. The effective tax rate was 0.0%.
Operating cash flow was $49K (down 81% year over year), 86% of net earnings. Non-cash charges added back $56K of depreciation and amortization and $63K of share-based compensation. Working capital and other items used $127K. Capital expenditures of $3K left free cash flow of $46K.
Questions
What was International Stem Cell's revenue in the third quarter 2025?
International Stem Cell (ISCO) reported revenue of $2.4M for the third quarter 2025 (Q3 2025), +9% from a year earlier and -3% from the quarter before.
Was International Stem Cell profitable in the third quarter 2025?
Operating profit was $94K (4.0% of revenue) and net earnings $57K.